Other broadly acting immunosuppressives such as corticosteroids or more targeted modulation with IL-6 inhibitors (tocilizumab) and Janus-kinase (JAK) inhibitors (baricitinib) have now become standard of care for managing hyperinflammation in severe COVID-19. Here, IL6 is linked to COVID-19.